Trial intelligence / Profile preview

PREDATOR

2024-518400-50-00Phase 2Completed

Sponsor: Polish Myeloma Consortium
Start: Dec 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 2, randomised trial in multiple myeloma (MM) comparing Daratumumab arm with Observation arm (2 arms). Primary endpoints: Event-free survival (EFS) in biochemical relapse cohort and Event-free survival (EFS) in MRD reappearance cohort. Started Dec 2024; status: completed.

Drugs

daratumumab

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on 2024-518400-50-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-518400-50-00.